What is it about?
PA-824 is currently under clinical development for the treatment of tuberculosis. We synthesised S-PA-824 and its mirror image form (R-PA824) and found that both were active against leismania parasites grown in macrophages. However, the R-form, which is essentially inactive againt the tubercle bacillus, was more active than the S-form against leishmania. The R-form was also found to be active in a mouse model of visceral leishmaniasis.
Photo by freestocks.org on Unsplash
Why is it important?
R-PA824 is a new potential treatment for visceral leishmaniasis. How it works is not known, other than it is different to how fexinidazole works in leishmaniasis and different to how S-PA-824 is thought to work against the tubercle bacillus. Further safety studies are necessary before it could be considered for clinical trials.
Read the Original
This page is a summary of: TheREnantiomer of the Antitubercular Drug PA-824 as a Potential Oral Treatment for Visceral Leishmaniasis, Antimicrobial Agents and Chemotherapy, July 2013, ASM Journals,
You can read the full text:
The following have contributed to this page